Get the Stockscreener App
1.18
0.00%
0.00
Climb Bio Inc stock is traded at $1.18, with a volume of 114.02K.
It is up +0.00% in the last 24 hours and down -7.09% over the past month.
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.
See More
Previous Close:
$1.18
Open:
$1.18
24h Volume:
114.02K
Relative Volume:
0.72
Market Cap:
$79.74M
Revenue:
-
Net Income/Loss:
$-64.20M
P/E Ratio:
-0.5488
EPS:
-2.15
Net Cash Flow:
$57,000
1W Performance:
+0.00%
1M Performance:
-7.09%
6M Performance:
-63.80%
1Y Performance:
+0.00%
1-Day Range:
$1.16
$1.23
1-Week Range:
$1.16
$1.28
52-Week Range:
$1.05
$5.47
Climb Bio Inc Stock (CLYM) Company Profile
Name
Climb Bio Inc
Sector
Industry
Phone
1-866-857-2596
Address
20 WILLIAM STREET, WELLESLEY HILLS
Compare CLYM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLYM
Climb Bio Inc
|
1.18 | 79.06M | 0 | -64.20M | 57,000 | -2.15 |
|
ONC
Beone Medicines Ltd Adr
|
245.93 | 25.76B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.43 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.415 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
84.10 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.81 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Climb Bio Inc Stock (CLYM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-22-25 | Initiated | BTIG Research | Buy |
| Dec-02-24 | Initiated | Leerink Partners | Outperform |
Climb Bio Inc Stock (CLYM) Latest News
BNP Paribas Financial Markets Has $69,000 Stock Holdings in Climb Global Solutions, Inc. (NASDAQ:CLMB) - Defense World
Climb Bio (NASDAQ:CLYM) Upgraded at BTIG Research - Defense World
Are Wall Street Analysts Predicting Agilent Technologies Stock Will Climb or Sink? - MSN
Climb Bio Appoints Interim CFO Amid Leadership Change - TipRanks
2 S&P 500 Stocks to Buy Now On the Dip for Huge Upside - Yahoo Finance
BTIG sets Climb Bio stock Buy rating, $7 target By Investing.com - Investing.com Nigeria
BTIG sets Climb Bio stock Buy rating, $7 target - Investing.com
BioArctic shares climb on Q1 profit beat, boosted by Bristol payment - Investing.com Canada
Strong week for Access Bio (KOSDAQ:950130) shareholders doesn't alleviate pain of three-year loss - simplywall.st
Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
What is Leerink Partnrs’ Estimate for Climb Bio Q2 Earnings? - Defense World
Climb Bio Awards $152K Stock Package to New Executive: Inside the Biotech's Latest Talent Investment - Stock Titan
Climb Bio Reports Increased Losses Amid Ongoing Development - TipRanks
Climb Bio Reports First Quarter 2025 Financial Results and Provides Business Updates - The Manila Times
Tilray Brands Announces the Launch of XMG Atomic Sours: New THC Beverages and Edibles - The Manila Times
Climb Bio reports Q1 EPS (31c) vs (6c) last year - TipRanks
Climb Bio, Inc. SEC 10-Q Report - TradingView
Climb Bio (CLYM) Expected to Announce Earnings on Wednesday - Defense World
Life sciences firms climb after US and China agree to cut tariffs - TradingView
Exec Edge Launches Research Coverage with Initiation Notes on FL - GuruFocus
Exec Edge Launches Research Coverage with Initiation Notes on FLD, CLYM, STKS, REX, ACB - Quantisnow
Market Update: Climb Bio Inc (CLYM) Sees Positive Movement, Closing at 1.21 - DWinneX
Stock Index Futures Climb on U.S.-China Trade Talk Optimism, Fed Rate Decision in Focus - The Globe and Mail
Astaxanthin Market Size to Climb USD 6.86 Billion by 2034 - Precedence Research
Dollar Falls and Gold Prices Climb on US Trade Uncertainty - The Globe and Mail
Jim Cramer on Netflix, Inc. (NFLX): ‘I Bet This One Can Continue to Climb Over the Long Haul’ - Yahoo Finance
Sugar Prices Slump on Expectations for Robust Global Supplies - The Globe and Mail
Kospi continues to climb gradually amid auto and bio gains - MSN
Stock market today: Dow extends longest win streak of 2025 as S&P 500, Nasdaq climb after latest tariff relief - Yahoo Finance
Tevogen Bio Holdings Stock Is Soaring After Hours: What's Going On? - Benzinga
F5 shares climb after earnings and revenue exceed analyst forecasts - SiliconANGLE
Hair Transplant System Market Expected to Climb to USD 44.24 Billion by 2032, Rising at 21.6% CAGR - openPR.com
Piper Sandler Remains a Buy on Solid Biosciences (SLDB) - The Globe and Mail
Virtual Cardiology Market Expected to Climb from USD 1.7 Billion in 2025 to USD 4.2 Billion by 2032 - openPR.com
Climb Bio Inc (NASDAQ: CLYM): On Track To A Higher Share Price - Stocksregister
Most active stocks: US stocks with the highest trading volume today - Yahoo
Sugar Prices Climb on Reduced Sugar Output in India - The Globe and Mail
UnitedHealth reports 'unusual and unacceptable' earnings as Medicare costs climb - Endpoints News
Netflix Stock Extends Recent Climb Ahead of Earnings Release - Investopedia
Enterprise AI Breakthrough: New Partnership Promises Hours-Fast Implementation for Fortune 500 Companies - Stock Titan
3,756 Shares in Climb Global Solutions, Inc. (NASDAQ:CLMB) Purchased by Arrowstreet Capital Limited Partnership - Defense World
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Exec Edge Launches Research Coverage with Initiation Notes on FLD, CLYM, STKS, REX - Yahoo Finance
Happy Joe’s, Sacco climb top industry Movers & Shakers list - Quad Cities Business Journal
CLYM stock touches 52-week low at $1.2 amid market challenges - Investing.com Australia
Climb Bio expands board with two new directors - Investing.com Australia
Climb Bio expands board with two new directors By Investing.com - Investing.com Canada
Climb Bio appoints Kim Cobleigh Drapkin, Bo Cumbo to board - TipRanks
Climb Bio Expands Board with New Director Appointments - TipRanks
Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors - The Manila Times
INmune Bio Inc. Presents Baseline Demographics and Disease Profiles of Participants in the MINDFuL Phase II Study - The Manila Times
Climb Bio Inc Stock (CLYM) Financials Data
Revenue
Net Income
Cash Flow
EPS
6.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):